IP6K1: Key Player in Inositol Signaling Pathway (G9807)

Target Name: IP6K1

NCBI ID: G9807

IP6K1

IP6K1: Key Player in Inositol Signaling Pathway

IP6K1 (ATP:1D-myo-inositol-hexakisphosphate phosphotransferase) is a protein that is expressed in various tissues, including muscle, heart, and brain. It is involved in the intracellular signaling pathway known as the inositol signaling pathway, which plays a crucial role in regulating various cellular processes, including muscle contractions and cell survival. The IP6K1 enzyme is a key player in this pathway, as it catalyzes the transfer of inositol from IP6K2 to IP6K3, which is a critical step in the pathway.

IP6K1 is a member of the family of transmembrane protein kinases, which are characterized by their ability to span the cell membrane and interact with various intracellular signaling molecules. The IP6K1 enzyme is involved in the regulation of inositol signaling pathway, which is a critical pathway that regulates various cellular processes, including muscle contractions and cell survival.

Drugs that target IP6K1 have the potential to be valuable therapeutic options for various diseases. For example, IP6K1 has been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, IP6K1 has also been shown to be involved in the regulation of muscle contractions, which makes it a potential target for muscle-related diseases, such as myopathies.

IP6K1 functions as a kinase that transfers IP6K2 to IP6K3. IP6K2 is a protein that is characterized by its ability to bind to the IP6K1 enzyme. Once bound, IP6K2 activates IP6K1, which then catalyzes the transfer of IP6K3 to IP6K2. This transfer of IP6K3 to IP6K2 is the final step in the inositol signaling pathway.

The inositol signaling pathway is a critical pathway that regulates various cellular processes, including muscle contractions, cell survival, and neurotransmission. IP6K1 is a key player in this pathway, as it catalyzes the transfer of IP6K2 to IP6K3, which is the final step in the pathway.

Studies have shown that IP6K1 is involved in the regulation of various cellular processes, including muscle contractions, cell survival, and neurotransmission. For example, IP6K1 has been shown to be involved in the regulation of muscle contractions, as it has been shown to play a role in the development and progression of various muscle-related diseases, including myopathies.

Additionally, IP6K1 has also been shown to be involved in the regulation of cell survival, as it has been shown to play a role in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, IP6K1 is a protein that is involved in the regulation of various cellular processes, including muscle contractions, cell survival, and neurotransmission. The IP6K1 enzyme has been shown to play a role in the development and progression of various muscle-related diseases, as well as in the regulation of cell survival in neurodegenerative diseases. Therefore, IP6K1 is a potential drug target and biomarker for various diseases.

Protein Name: Inositol Hexakisphosphate Kinase 1

Functions: Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). Converts 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4

The "IP6K1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IP6K1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets